Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

372 ARTÍCULOS , VIENDO DEL 331 AL 345

Secretases as therapeutic targets for Alzheimer's disease

Woo HN, Baik SH, Park JS, Gwon AR, Yang S, Yun YK, Jo DG.

Biochem Biophys Res Commun. 2011 Jan 7;404(1):10-5. doi: 10.1016/j.bbrc.2010.11.132. Epub 2010 Dec 3.

Neurotherapeutic applications of nanoparticles in Alzheimer's disease

Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C.

J Control Release. 2011 Jun 10;152(2):208-31. doi: 10.1016/j.jconrel.2010.11.033. Epub 2010 Dec 4.

Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice

Rozkalne A, Hyman BT, Spires-Jones TL.

Neurobiol Dis. 2011 Mar;41(3):650-4. doi: 10.1016/j.nbd.2010.11.014. Epub 2010 Dec 4.

γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs

Oehlrich D, Berthelot DJ, Gijsen HJ.

J Med Chem. 2011 Feb 10;54(3):669-98. doi: 10.1021/jm101168r. Epub 2010 Dec 9.

Genistein ameliorates learning and memory deficits in amyloid β(1-40) rat model of Alzheimer's disease

Bagheri M, Joghataei MT, Mohseni S, Roghani M.

Neurobiol Learn Mem. 2011 Mar;95(3):270-6. doi: 10.1016/j.nlm.2010.12.001. Epub 2010 Dec 7.

Citicoline in vascular cognitive impairment and vascular dementia after stroke

Alvarez-Sabín J, Román GC.

Stroke. 2011 Jan;42(1 Suppl):S40-3. doi: 10.1161/STROKEAHA.110.606509. Epub 2010 Dec 16.

Atorvastatin and Aβ(1-40): not as simple as cholesterol reduction in brain and relevance to Alzheimer disease

Butterfield DA.

Exp Neurol. 2011 Mar;228(1):15-8. doi: 10.1016/j.expneurol.2010.12.014. Epub 2010 Dec 28.

Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action

Barone E, Cenini G, Di Domenico F, Martin S, Sultana R, Mancuso C, Murphy MP, Head E, Butterfield DA.

Pharmacol Res. 2011 Mar;63(3):172-80. doi: 10.1016/j.phrs.2010.12.007. Epub 2010 Dec 27.

Endothelin receptor antagonists: potential in Alzheimer's disease

Palmer J, Love S.

Pharmacol Res. 2011 Jun;63(6):525-31. doi: 10.1016/j.phrs.2010.12.008. Epub 2010 Dec 27.

Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study

Kennelly SP, Abdullah L, Paris D, Parish J, Mathura V, Mullan M, Crawford F, Lawlor BA, Kenny RA.

Int J Geriatr Psychiatry. 2011 Oct;26(10):1038-45. doi: 10.1002/gps.2638. Epub 2010 Oct 29.

The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease

Mitchell RA, Herrmann N, Lanctôt KL.

CNS Neurosci Ther. 2011 Oct;17(5):411-27. doi: 10.1111/j.1755-5949.2010.00161.x. Epub 2010 Jun 16.

Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality

Ballard C, Creese B, Corbett A, Aarsland D.

Expert Opin Drug Saf. 2011 Jan;10(1):35-43. doi: 10.1517/14740338.2010.506711. Epub 2010 Aug 5.

Third degree heart block following intramuscular ziprasidone

Tambyraja R, Strawn JR.

Schizophr Res. 2011 Feb;125(2-3):302-3. doi: 10.1016/j.schres.2010.07.015. Epub 2010 Aug 7.

Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report

Na HR, Kim S, Choi SH, Yang DW, Bae HJ, Kim JE, Park MY, Shim YS, Kim BK, Kwon JC, Yoo BG, Kim BC, Lee JS.

Geriatr Gerontol Int. 2011 Jan;11(1):90-7. doi: 10.1111/j.1447-0594.2010.00649.x. Epub 2010 Sep 3.

A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease

Geldmacher DS, Fritsch T, McClendon MJ, Landreth G.

Arch Neurol. 2011 Jan;68(1):45-50. doi: 10.1001/archneurol.2010.229. Epub 2010 Sep 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias